TITomoko Iwata

Tomoko Iwata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tomoko Iwata has a total of 143 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Novel adenoma-immune phenotypes are associated with risk of metachronous polyps and colorectal cancer in a bowel screening cohort

    by Stephen T. McSorley, Tomoko Iwata, Aula Ammar, Sara S.F. Al-Badran, Lewis Irvine, Claire Kennedy Dietrich, Assya Legrini, Marjolein R. de Koning, Natalie Fisher, Emma C. Parsons, et al.

  • Open Access

    Mentoring scheme as a driver of equality, diversity and inclusion in health professions education and research

    by Sue Campbell, Rafael Henry-Venson, Claire Fitton, Caroline M Allen, Konstantinos Gkikas, Tomoko Iwata

    Mentoring is one of the important modalities that are known to enhance professional development of staff, including those who engage in teaching and learning of Health Professions in Higher Education as well as research of patients-focused subjects. However, while multiple mentoring schemes are available at University level, the impact they bring to the local community of staff is often unclear. With an aim to identify the current status of mentoring within the School of Medicine, Dentistry and Nursing, University of Glasgow, the Athena Swan-led Aspiration and Development Working Group has conducted a reflective study. We analysed benefits of the existing mentoring schemes, as well as challenges met by staff in the early stages of career in the Learning, Teaching and Scholarship and the Research and Teaching tracks. Reflection was also made on the equality, diversity and inclusion of Postgraduate Research students and LGBTQ+ members of the community. We have found that there was a limited uptake despite benefits, and that there were multiple causes for this, which was beyond a lack of time. This has led to a proposal of a new mentoring scheme that focuses on local needs and the process that centres more favourably to the prospective mentees, by reducing the hurdle for participation and providing more flexibility in the format, frequency and content, with an integrated monitoring platform of the scheme, which supports sustainability. We find that, for provision of a meaningful mentoring, careful design and implementation based on the EDI ethos is essential.

  • Open Access

    Why early pathology input matters in biologically rich cancer trials

    by Manas Dave, Maggie Chon U. Cheang, Guy Betts, Tomoko Iwata, Michelle Frost, Chiara Braconi, Menna Shamma, Timothy J. Kendall

    Pathology is central to many biologically driven cancer clinical trials. Biomarker-led and translational studies depend on robust tissue pathways, cellular and molecular assays, pathology-derived endpoints, and clinically meaningful interpretation of discovery science. Where trials depend on tumour material, biomarker-defined eligibility or mechanism-focused endpoints, pathology expertise should be embedded early, before protocols, budgets, and assays are fixed. Early pathology input strengthens feasibility, specimen governance, assay selection, quality assurance, and the long-term value of collected samples. In the UK, the Clinical Trials Pathology Advisory Group, now within the new Pathological Society of Great Britain and Ireland Clinical Trials Pathology subcommittee, provides a practical route for pre-submission specialist review. This Perspective argues that pathology is core infrastructure for biologically rich trials, linking discovery science to clinical translation.


  • Open Access

    Mentoring scheme as a driver of equality, diversity and inclusion in health professions education and research

    by Sue Campbell, Rafael Venson, Claire Fitton, Caroline Allen, Konstantinos Gkikas, Tomoko Iwata

    Mentoring is one of the important modalities that are known to enhance professional development of staff, including those who engage in teaching and learning of Health Professions in Higher Education as well as research of patients-focused subjects. However, while multiple mentoring schemes are available at University level, the impact they bring to the local community of staff is often unclear. With an aim to identify the current status of mentoring within School of Medicine, Dentistry and Nursing, University of Glasgow, the Athena Swan-led Aspiration and Development Working Group has conducted a reflective study. We analysed benefits of the existing mentoring schemes, as well as challenges met by staff in the early stages of career in the Learning, Teaching and Scholarship and the Research and Teaching tracks. Reflection was also made on the equality, diversity and inclusion of Postgraduate Research students and LGBTQ+ members of the community. We have found that there was a limited uptake despite benefits, and that there were multiple causes for this, which was beyond a lack of time. This has led to a proposal of a new mentoring scheme that focuses on local needs and the process that centres more favourably to the prospective mentees, with an integrated monitoring platform of the scheme, which supports sustainability. We find that, for provision of a meaningful mentoring, careful design and implementation based on the EDI ethos is essential.

  • The Emerging Landscape of Mouse Bladder Cancer Models

    by Tomoko Iwata, Amal Rahil Elgaddafi Yousef

  • Open Access

    Empagliflozin in Heart Failure with Preserved Ejection Fraction with and without Atrial Fibrillation

    by Gerasimos Filippatos, Dimitrios Farmakis, Javed Butler, Faiez Zannad, João Pedro Ferreira, Anne Pernille Ofstad, Tomoko Iwata, Martina Brueckmann, Stuart J. Pocock, Milton Packer, et al.

    Aims: Atrial fibrillation/flutter (AF) is common in heart failure (HF) with preserved left ventricular ejection fraction (LVEF) and associated with worse outcomes. Empagliflozin reduces cardiovascular death or HF hospitalizations and slows estimated glomerular filtration rate (eGFR) decline in patients with HF and LVEF >40%. We aimed to assess the efficacy and safety of empagliflozin in improving outcomes in patients with HF and LVEF >40% with and without AF. Methods and results: In this pre-defined secondary analysis of EMPEROR-Preserved, we compared the effects of empagliflozin versus placebo on the primary and secondary endpoints and safety outcomes, stratified by baseline AF, defined as AF reported in any electrocardiogram before empagliflozin initiation or in medical history. Among 5988 patients randomized, 3135 (52%) had baseline AF; these patients were older, with worse functional class, more previous HF hospitalizations and higher natriuretic peptides compared to those without AF (all p < 0.001). After a median of 26 months, empagliflozin reduced cardiovascular death or HF hospitalization compared to placebo to a similar extent in patients with and without AF (hazard ratio [HR] 0.78 [95% confidence interval 0.66–0.93] vs. 0.78 [0.64–0.95], interaction p = 0.96). Empagliflozin also reduced total HF hospitalizations (HR 0.73 [0.57–0.94] vs. 0.72 [0.54–0.95], interaction p = 0.94) and annual eGFR decline (difference = 1.368 vs. 1.372 ml/min/1.73 m2/year, interaction p = 0.99) consistently in patients with and without AF. There was no increase in serious adverse events with empagliflozin versus placebo in patients with and without AF. Conclusions: In patients with HF and ejection fraction >40%, empagliflozin reduced the risk of serious HF events and slowed the eGFR decline regardless of baseline AF.


  • Open Access

    Loss of Cxcr2 in Myeloid Cells Promotes Tumour Progression and T Cell Infiltration in Invasive Bladder Cancer

    by Nur Faezah Binti Ismail, Mona Foth, Amal Rahil Elgaddafi Yousef, Ningxuan Cui, Joshua D.G. Leach, Thomas Jamieson, Saadia A. Karim, Jonathan M. Salmond, Jennifer P. Morton, Tomoko Iwata

    BACKGROUND: CXCR2 is a chemokine receptor expressed in myeloid cells, including neutrophils and macrophages. Pharmacological inhibition of CXCR2 has been shown to sensitize tumours to immune checkpoint inhibitor immunotherapies in some cancer types. OBJECTIVE: To investigate the effects of CXCR2 loss in regulation of tumour-infiltrating myeloid cells and their relationship to lymphocytes during bladder tumorigenesis. METHODS: Urothelial pathogenesis and immune contexture was investigated in an OH-BBN model of invasive bladder cancer with Cxcr2 deleted in myeloid cells ( LysMCre Cxcr2 flox/flox ). CXCR2 gene alterations and expression in human muscle invasive bladder cancer were analysed in The Cancer Genome Atlas. RESULTS: Urothelial tumour pathogenesis was significantly increased upon Cxcr2 deletion compared to wildtype mice. This was associated with a suppression of myeloid cell infiltration in Cxcr2-deleted bladders shortly after the carcinogen induction. Interestingly, following a transient increase of macrophages at the outset of tumour formation, an increase in T cell infiltration was observed in Cxcr2-deleted tumours. The increased tumour burden in the Cxcr2-deleted bladder was largely independent of T cells and the status of immune suppression. The Cxcr2-deleted mouse model reflected the low CXCR2 mRNA range in human bladder cancer, which showed poor overall survival. CONCLUSIONS: In contrast to previous reports of increased CXCR2 signalling associated with disease progression and poor prognosis, CXCR2 was protective against bladder cancer during tumour initiation. This is likely due to a suppression of acute inflammation. The strategy for sensitizing checkpoint immunotherapy by CXCR2 inhibition in bladder cancer may benefit from an examination of immune suppressive status.


  • Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays

    by John J.G. Pritchard, Graham Hamilton, Carolyn D. Hurst, Sioban Fraser, Clare Orange, Margaret A. Knowles, Robert J. Jones, Hing Y. Leung, Tomoko Iwata


  • Open Access

    FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation

    by Mona Foth, Nur Faezah Binti Ismail, Jeng Sum Charmaine Kung, Darren Tomlinson, Margaret A Knowles, Pontus Eriksson, Gottfrid Sjödahl, Jonathan M. Salmond, Owen J. Sansom, Tomoko Iwata

    Recent studies of muscle‐invasive bladder cancer show that FGFR3 mutations are generally found in a luminal papillary tumour subtype that is characterised by better survival than other molecular subtypes. To better understand the role of FGFR3 in invasive bladder cancer, we examined the process of tumour development induced by the tobacco carcinogen OH‐BBN in genetically engineered models that express mutationally activated FGFR3 S249C or FGFR3 K644E in the urothelium. Both occurrence and progression of OH‐BBN‐driven tumours were increased in the presence of an S249C mutation compared to wild‐type control mice. Interestingly, at an early tumour initiation stage, the acute inflammatory response in OH‐BBN‐treated bladders was suppressed in the presence of an S249C mutation. However, at later stages of tumour progression, increased inflammation was observed in S249C tumours, long after the carcinogen administration had ceased. Early‐phase neutrophil depletion using an anti‐Ly6G monoclonal antibody resulted in an increased neutrophil‐to‐lymphocyte ratio at later stages of pathogenesis, indicative of enhanced tumour pathogenesis, which supports the hypothesis that suppression of acute inflammation could play a causative role. Statistical analyses of correlation showed that while initial bladder phenotypes in morphology and inflammation were FGFR3‐dependent, increased levels of inflammation were associated with tumour progression at the later stage. This study provides a novel insight into the tumour‐promoting effect of FGFR3 mutations via regulation of inflammation at the pre‐tumour stage in the bladder. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.


  • Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice

    by Mona Foth, Imran Ahmad, Bas Wg van Rhijn, Theodorus van der Kwast, Andre M Bergman, Louise King, Rachel Ridgway, Hing Y Leung, Sioban Fraser, Owen J Sansom, et al.

    Although somatic mutations and overexpression of the tyrosine kinase fibroblast growth factor receptor 3 (FGFR3) are strongly associated with bladder cancer, evidence for their functional involvement in the pathogenesis remains elusive. Previously we showed that activation of Fgfr3 alone is not sufficient to initiate urothelial tumourigenesis in mice. Here we hypothesize that cooperating mutations are required for Fgfr3‐dependent tumourigenesis in the urothelium and analyse a mouse model in which an inhibitor of Pi3k–Akt signalling, Pten, is deleted in concert with Fgfr3 activation (UroIICreFgfr3+/K644EPtenflox/flox). Two main phenotypical characteristics were observed in the urothelium: increased urothelial thickness and abnormal cellular histopathology, including vacuolization, condensed cellular appearance, enlargement of cells and nuclei, and loss of polarity. These changes were not observed when either mutation was present individually. Expression patterns of known urothelial proteins indicated the abnormal cellular differentiation. Furthermore, quantitative analysis showed that Fgfr3 and Pten mutations cooperatively caused cellular enlargement, while Pten contributed to increased cell proliferation. Finally, FGFR3 overexpression was analysed along the level of phosphorylated mTOR in 66 T1 urothelial tumours in tissue microarray, which supported the occurrence of functional association of these two signalling pathways in urothelial pathogenesis. Taken together, this study provides evidence supporting a functional role of FGFR3 in the process of pathogenesis in urothelial neoplasms. Given the wide availability of inhibitors specific to FGF signalling pathways, our model may open the avenue for FGFR3‐targeted translation in urothelial disease. Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.